Compare ATNM & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATNM | ORIS |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.2M | 41.2M |
| IPO Year | N/A | 2024 |
| Metric | ATNM | ORIS |
|---|---|---|
| Price | $1.33 | $1.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 137.7K | ★ 650.4K |
| Earning Date | 11-14-2025 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | $90,000.00 | ★ $12,317,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $197.24 |
| Revenue Growth | ★ 11.11 | N/A |
| 52 Week Low | $1.03 | $1.11 |
| 52 Week High | $2.41 | $45.60 |
| Indicator | ATNM | ORIS |
|---|---|---|
| Relative Strength Index (RSI) | 42.97 | 64.15 |
| Support Level | $1.27 | $1.11 |
| Resistance Level | $1.36 | $1.87 |
| Average True Range (ATR) | 0.07 | 0.20 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 26.00 | 75.32 |
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).